DSM-IV to DSM-5 (ICD-10) CROSSWALK

Total Page：16

File Type：pdf, Size：1020Kb

ALCOHOL AND OTHER DRUG SERVICES DSM-IV to DSM-5 (ICD-10) CROSSWALK DSM-IV DSM-5 (ICD-10) 303.90 ALCOHOL DEPENDENCE 303.90 (F10.20) ALCOHOL USE DISORDER MODERATE/SEVERE 305.00 ALCOHOL ABUSE 305.00 (F10.10) ALCOHOL USE DISORDER MILD 304.40 AMPHETAMINE DEPENDENCE 304.40 (F15.20) AMPHETAMINE-TYPE SUBSTANCE USE DISORDER MODERATE/SEVERE 305.70 AMPHETAMINE ABUSE 305.70 (F15.10) AMPHETAMINE-TYPE SUBSTANCE USE DISORDER MILD 304.20 COCAINE DEPENDENCE 304.20 (F14.20)COCAINE USE DISORDER MODERATE/SEVERE 305.60 COCAINE ABUSE 305.60 (F14.10) COCAINE USE DISORDER MILD NONE FOR ‘UNSPECIFIED’ STIMULANT DEPENDENCE 304.40 (F15.10) OTHER/UNSPECIFIED STIMULANT USE DISORDER MODERATE/SEVERE NONE FOR ‘UNSPECIFIED’ STIMULANT ABUSE 305.70 (F15.10) OTHER/UNSPECIFIED STIMULANT USE DISORDER MILD 304.10 SEDATIVE HYPNOTIC/ANXIOLYTIC DEPENDENCE 304.10 (F13.20) SEDATIVE HYPNOTIC/ANXIOLYTIC MODERATE/SEVERE 305.40 SEDATIVE HYPNOTIC/ANXIOLYTIC ABUSE 305.40 (F13.10) SEDATIVE HYPNOTIC/ANXIOLYTIC MILD 304.30 CANNABIS DEPENDENCE 304.30 (F12.20) CANNABIS USE DISORDER MODERATE/SEVERE 305.20 CANNABIS ABUSE 305.20 (F12.10) CANNABIS USE DISORDER MILD 304.50 HALLUCINOGEN DEPENDENCE 304.50 (F16.20) OTHER HALLUCINOGEN USE DISORDER MODERATE/SEVERE 305.30 HALLUCINOGEN ABUSE 305.30 (F16.10) OTHER HALLUCINOGEN USE DISORDER MILD 304.60 INHALANT DEPENDENCE 304.60 (F18.20) INHALANT USE DISORDER MODERATE/SEVERE 305.90 INHALANT ABUSE 305.90 (F18.10) INHALANT USE DISORDER MILD DSM-IV to DSM-5 (ICD-10) Crosswalk CCC AODS ALCOHOL AND OTHER DRUG SERVICES DSM-IV DSM-5 (ICD-10) 304.60 PCP DEPENDENCE 304.60 (F16.20) PHENCYCLYDINE USE DISORDER MODERATE/SEVERE 305.90 PCP ABUSE 305.90 (F16.10) PHENCYCLYDINE USE DISORDER MILD 304.00 OPIOID DEPENDENCE 304.00 (F11.20) OPIOID USE DISORDER MODERATE/SEVERE 305.50 OPIOID ABUSE 305.50 (F11.10) OPIOID USE DISORDER MILD 304.90 OTHER/UNKNOWN SUBSTANCE DEPENDENCE 304.90 (F19.20) OTHER (UNKNOWN) SUBSTANCE USE DISORDER MODERATE/SEVERE 305.90 OTHER/UNKNOWN SUBSTANCE ABUSE 305.90 (F19.10) OTHER (UNKNOWN) SUBSTANCE USE DISORDER MILD 304.80 POLYSUBSTANCE DEPENDENCE NONE – CANNOT USE THIS ANYMORE 799.9 DIAGNOSIS DEFERRED 799.9 (R69) DIAGNOSIS DEFERRED – BUT USE A SECONDARY SUD DIAGNOSIS INSTEAD DSM-IV to DSM-5 (ICD-10) Crosswalk CCC AODS .

Copy Link

Recommended publications

Smoking Cessation Treatment at Substance Abuse Rehabilitation Programs
SMOKING CEssATION TREATMENT AT SUBSTANCE ABUSE REHABILITATION PROGRAMS Malcolm S. Reid, PhD, New York University School of Medicine, Department of Psychiatry; Jeff Sel- zer, MD, North Shore Long Island Jewish Healthcare System; John Rotrosen, MD, New York University School of Medicine, Department of Psychiatry Cigarette smoking is common among persons with drug and alcohol n Nicotine is a highly use disorders, with prevalence rates of 80-90% among patients in sub- addictive substance stance use disorder treatment programs. Such concurrent smoking may that meets all of produce adverse behavioral and medical problems, and is associated the criteria for drug with greater levels of substance use disorder. dependence. CBehavioral studies indicate that the act of cigarette smoking serves as a cue for drug and alcohol craving, and the active ingredient of cigarettes, nicotine, serves as a primer for drug and alcohol abuse (Sees and Clarke, 1993; Reid et al., 1998). More critically, longitudinal studies have found tobacco use to be the number one cause of preventable death in the United States, and also the single highest contributor to mortality in patients treated for alcoholism (Hurt et al., 1996). Nicotine is a highly addictive substance that meets all of the criteria for drug dependence, and cigarette smoking is an especially effective method for the delivery of nicotine, producing peak brain levels within 15-20 seconds. This rapid drug delivery is one of a number of common properties that cigarette smok- ing shares with hazardous drug and alcohol use, such as the ability to activate the dopamine system in the reward circuitry of the brain.
[Show full text]
Treatment of Stimulant Use Disorders
UW PACC Psychiatry and Addictions Case Conference UW Medicine | Psychiatry and Behavioral Sciences TREATMENT OF STIMULANT USE DISORDERS Matt Iles-Shih, MD Addiction Psychiatry Fellow University Of Washington & VA Puget Sound Health Care System UW PACC ©2017 University of Washington GENERAL DISCLOSURES The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State. UW PACC ©2017 University of Washington SPEAKER DISCLOSURES No conflicts of interest/disclosures UW PACC ©2017 University of Washington OBJECTIVES 1. Brief overview of stimulant-related physiology & epidemiology 2. Recognizing & treating stimulant use disorders: . Diagnosis & management of acute effects (brief) . Psychotherapies (brief) . Pharmacotherapies 3. Special populations – ADHD in stimulant-abusing pts: to Rx, and how? UW PACC ©2017 University of Washington STIMULANTS: What Substances Are We Talking About? Cocaine Amphetamines: – Prescription Meds – Methamphetamine – Multiple other modified amphetamines MDMA (3,4-methylenedioxy-methamphetamine) [Note: mixed stimulant-psychodelic properties, w/↑serotonin > dopamine and abuse >> addiction.] Others: – Cathinones: Khat & Synthetics (e.g., “Bath Salts”) – Piperazine-like substances (various) – Phenylaklylpyrrolidines (various) UW PACC ©2017 University of Washington COMMONALITIES (WHAT MAKES A STIMULANT
[Show full text]
Substance Abuse and Dependence
9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine.
[Show full text]
GABA Systems, Benzodiazepines, and Substance Dependence
Robert J. Malcolm GABA Systems, Benzodiazepines, and Substance Dependence Robert J. Malcolm, M.D. Alterations in the γ-aminobutyric acid (GABA) receptor complex and GABA neurotransmission influence the reinforcing and intoxicating effects of alcohol and benzodiazepines. Chronic modulation of the GABAA-benzodiazepine receptor complex plays a major role in central nervous system dysregulation during alcohol abstinence. Withdrawal symptoms stem in part from a decreased GABAergic inhibitory function and an increase in glutamatergic excitatory function. GABAA recep- tors play a role in both reward and withdrawal phenomena from alcohol and sedative-hypnotics. Although less well understood, GABAB receptor complexes appear to play a role in inhibition of moti- vation and diminish relapse potential to reinforcing drugs. Evidence suggests that long-term alcohol use and concomitant serial withdrawals permanently alter GABAergic function, down-regulate ben- zodiazepine binding sites, and in preclinical models lead to cell death. Benzodiazepines have substan- tial drawbacks in the treatment of substance use–related disorders that include interactions with alco- hol, rebound effects, alcohol priming, and the risk of supplanting alcohol dependency with addiction to both alcohol and benzodiazepines. Polysubstance-dependent individuals frequently self-medicate with benzodiazepines. Selective GABA agents with novel mechanisms of action have anxiolytic, anticonvulsant, and reward inhibition profiles that have potential in treating substance use and with- drawal and enhancing relapse prevention with less liability than benzodiazepines. The GABAB receptor agonist baclofen has promise in relapse prevention in a number of substance dependence dis- orders. The GABAA and GABAB pump reuptake inhibitor tiagabine has potential for managing alcohol and sedative-hypnotic withdrawal and also possibly a role in relapse prevention.
[Show full text]
Medications to Treat Opioid Use Disorder Research Report
Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
[Show full text]
International Standards for the Treatment of Drug Use Disorders
"*+,-.*--- -!"#$%&-'",()0"ÿ23 45 "6789!"7(@&A($!7,0B"67$!C#+D"%"*+,9779C&B"!7%EE F33"*+,-.*--- -!"#$%&-'",()0" International standards for the treatment of drug use disorders REVISED EDITION INCORPORATING RESULTS OF FIELD-TESTING International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing ISBN 978-92-4-000219-7 (electronic version) ISBN 978-92-4-000220-3 (print version) © World Health Organization and United Nations Office on Drugs and Crime, 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO or UNODC endorses any specific organization, products or services. The unauthorized use of the WHO or UNODC names or logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO) or the United Nations Office on Drugs and Crime (UNODC). Neither WHO nor UNODC are responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.
[Show full text]
Running Head: PHARMACOLOGICAL TREATMENT for METHAMPHETAMINE
Running head: PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE DEPENDENCE By BRINN CULVER A project submitted in partial fulfillment of the requirements for the degree of MASTER OF NURSING WASHINGTON STATE UNIVERSITY Department of Nursing APRIL 2014 PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE ii To the Faculty of Washington State University: The members of the Committee appointed to examine the dissertation/thesis of BRINN CULVER find it satisfactory and recommend that it be accepted. Julie DeWitt-Kamada, DNP, ARNP, PMHNP Chair Anne Mason, DNP, ARNP, PMHNP Dawn Rondeau, DNP, ACNP, FNP PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE iii PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE DEPENDENCE Abstract By Brinn Culver Washington State University April 2014 Chair: Julie DeWitt-Kamada Methamphetamine (MA) is a highly addictive drug whose abuse causes widespread global consequences. The negative impact of MA use on individuals and communities warrants its consideration as a public health concern. MA has a complicated pharmacological action, and chronic use results in neurological dysfunction, including deficits in dopamine. Changes in dopaminergic function make treatment of MA dependence especially challenging, and the mainstay treatment of psychotherapy is insufficient in addressing dopamine deficit. Pharmacological treatments are being explored, but no medication has attained Federal Drug Administration approval, as it requires proof of achieving abstinence. From a harm reduction standpoint, several
[Show full text]
Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs
Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs Douglas M. Ziedonis, M.D., M.P.H.; Joseph Guydish, Ph.D., M.P.H.; Jill Williams, M.D.; Marc Steinberg, Ph.D.; and Jonathan Foulds, Ph.D. Despite the high prevalence of tobacco use among people with substance use disorders, tobacco dependence is often overlooked in addiction treatment programs. Several studies and a meta-analytic review have concluded that patients who receive tobacco dependence treatment during addiction treatment have better overall substance abuse treatment outcomes compared with those who do not. Barriers that contribute to the lack of attention given to this important problem include staff attitudes about and use of tobacco, lack of adequate staff training to address tobacco use, unfounded fears among treatment staff and administration regarding tobacco policies, and limited tobacco dependence treatment resources. Specific clinical-, program-, and system-level changes are recommended to fully address the problem of tobacco use among alcohol and other drug abuse patients. KEY WORDS: Alcohol and tobacco; alcohol, tobacco, and other drug (ATOD) use, abuse, dependence; addiction care; tobacco dependence; smoking; secondhand smoke; nicotine; nicotine replacement; tobacco dependence screening; tobacco dependence treatment; treatment facility-based prevention; co-treatment; treatment issues; treatment barriers; treatment provider characteristics; treatment staff; staff training; AODD counselor; client counselor interaction; smoking cessation; Tobacco Dependence Program at the University of Medicine and Dentistry of New Jersey obacco dependence is one of to the other. The common genetic vul stance use was considered a potential the most common substance use nerability may be located on chromo trigger for the primary addiction.
[Show full text]
Cocaine Use Disorder
COCAINE USE DISORDER ABSTRACT Cocaine addiction is a serious public health problem. Millions of Americans regularly use cocaine, and some develop a substance use disorder. Cocaine is generally not ingested, but toxicity and death from gastrointestinal absorption has been known to occur. Medications that have been used as substitution therapy for the treatment of a cocaine use disorder include amphetamine, bupropion, methylphenidate, and modafinil. While pharmacological interventions can be effective, a recent review of pharmacological therapy for cocaine use indicates that psycho-social efforts are more consistent over medication as a treatment option. Introduction Cocaine is an illicit, addictive drug that is widely used. Cocaine addiction is a serious public health problem that burdens the healthcare system and that can be destructive to individual lives. It is impossible to know with certainty the extent of use but data from public health surveys, morbidity and mortality reports, and healthcare facilities show that there are millions of Americans who regularly take cocaine. Cocaine intoxication is a common cause for emergency room visits, and it is one drug that is most often involved in fatal overdoses. Some cocaine users take the drug occasionally and sporadically but as with every illicit drug there is a percentage of people who develop a substance use disorder. Treatment of a cocaine use disorder involves psycho-social interventions, pharmacotherapy, or a combination of the two. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com Pharmacology of Cocaine Cocaine is an alkaloid derived from the Erthroxylum coca plant, a plant that is indigenous to South America and several other parts of the world, and is cultivated elsewhere.
[Show full text]
DEMAND REDUCTION a Glossary of Terms
UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
[Show full text]
DIAGNOSIS REFERENCE GUIDE A. Diagnostic Criteria for Substance
ALCOHOL & OTHER DRUG SERVICES DIAGNOSIS REFERENCE GUIDE A. Diagnostic Criteria for Substance Use Disorder See DSM-5 for criteria specific to the drugs identified as primary, secondary or tertiary. P S T (P=Primary, S=Secondary, T=Tertiary) 1. Substance is often taken in larger amounts and/or over a longer period than the patient intended. 2. Persistent attempts or one or more unsuccessful efforts made to cut down or control substance use. 3. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from effects. 4. Craving or strong desire or urge to use the substance 5. Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home. 6. Continued substance use despite having persistent or recurrent social or interpersonal problem caused or exacerbated by the effects of the substance. 7. Important social, occupational or recreational activities given up or reduced because of substance use. 8. Recurrent substance use in situations in which it is physically hazardous. 9. Substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. 10. Tolerance, as defined by either of the following: a. Markedly increased amounts of the substance in order to achieve intoxication or desired effect; Which:__________________________________________ b. Markedly diminished effect with continued use of the same amount; Which:___________________________________________ 11. Withdrawal, as manifested by either of the following: a. The characteristic withdrawal syndrome for the substance; Which:___________________________________________ b.
[Show full text]
Meth/Amphetamine Use and Associated HIV: Implications for Global Policy and Public Health
International Journal of Drug Policy 21 (2010) 347–358 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locate/drugpo Review Meth/amphetamine use and associated HIV: Implications for global policy and public health Louisa Degenhardt ∗,1, Bradley Mathers 2, Mauro Guarinieri 3, Samiran Panda 4, Benjamin Phillips 5, Steffanie A. Strathdee 6, Mark Tyndall 7, Lucas Wiessing 8, Alex Wodak 9, John Howard 10, the Reference Group to the United Nations on HIV and injecting drug use National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia article info abstract Article history: Amphetamine type stimulants (ATS) have become the focus of increasing attention worldwide. There are Received 29 May 2009 understandable concerns over potential harms including the transmission of HIV. However, there have Received in revised form 30 October 2009 been no previous global reviews of the extent to which these drugs are injected or levels of HIV among Accepted 24 November 2009 users. A comprehensive search of the international peer-reviewed and grey literature was undertaken. Multiple electronic databases were searched and documents and datasets were provided by UN agencies and key experts from around the world in response to requests for information on the epidemiology of use. Keywords: Amphetamine or methamphetamine (meth/amphetamine, M/A) use was documented in 110 countries, Methamphetamine Amphetamine and injection in 60 of those. Use may be more prevalent in East and South East Asia, North America, South HIV Africa, New Zealand, Australia and a number of European countries. In countries where the crystalline Injecting form is available, evidence suggests users are more likely to smoke or inject the drug; in such countries, Epidemiology higher levels of dependence may be occurring.
[Show full text]